Welcome to our dedicated page for Fibrogen SEC filings (Ticker: FGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kyntra Bio SEC filings document the former FibroGen public-company record, including the completed 2026 name change and common-stock ticker transition from FGEN to KYNB. Material-event reports cover operating results, clinical and regulatory disclosures for FG-3246, FG-3180 and roxadustat, capital-structure matters, Nasdaq continued-listing compliance notices, and the completed sale of FibroGen International (Hong Kong) Ltd. and related pro forma financial information.
Proxy materials address shareholder voting matters, board and governance practices, executive compensation, equity awards and related corporate-control disclosures. The filing record also includes formal amendments to organizational documents and other 8-K disclosures tied to the company’s biopharmaceutical development focus and corporate transformation.
Thane Wettig, listed as CEO and Director of FibroGen, Inc. (FGEN), reported two stock disposals in 2025 and an indirect holding by his spouse. On 06/06/2025 he disposed of 21,487 shares at a reported price of $7.8325, and on 09/06/2025 he disposed of 21,239 shares at $12.10. The filing states these share amounts were withheld by the issuer to satisfy a tax obligation arising from the vesting of restricted stock units.
The form also notes an indirect beneficial ownership of 40 shares by his spouse. A 1-for-25 reverse stock split effective June 16, 2025 is disclosed and the reported share counts and prices reflect that split. The form is signed by an attorney-in-fact on behalf of the reporting person.
FibroGen, Inc. completed the sale of all issued and outstanding equity interests of its subsidiary FibroGen International (Hong Kong) Ltd. to AstraZeneca Treasury Limited on August 29, 2025 for approximately $220 million, closing a previously announced transaction under a Share Purchase Agreement dated February 20, 2025. The deal represents a disposition of assets associated with FibroGen’s China anemia business structure. The company also provided unaudited pro forma condensed consolidated financial information, including a balance sheet as of June 30, 2025 and statements of operations for the year ended December 31, 2024, in Exhibit 99.1 to help illustrate the financial impact of this divestiture.
FibroGen, Inc. reported that it has completed the sale of FibroGen International (Hong Kong) Ltd., including its FibroGen China operations, to AstraZeneca Treasury Limited for total consideration of approximately $220 million. This amount consists of $85 million in enterprise value and about $135 million in net cash held in China, with $6.0 million held back for final cash adjustments and $4.0 million held back for potential indemnity claims.
FibroGen and a subsidiary sold all equity interests in the Hong Kong entity and its China roxadustat assets to AstraZeneca, which has long partnered with FibroGen on roxadustat in greater China and South Korea. FibroGen keeps roxadustat rights in the United States, Canada, Mexico, and other territories not held by AstraZeneca or licensed to Astellas Pharma Inc. At closing, FibroGen repaid its term loan facility with investment funds managed by Morgan Stanley Tactical Value for approximately $81 million.
FibroGen, Inc. announced that Chinese regulators approved the proposed sale of FibroGen International (Hong Kong) Ltd. and its subsidiaries (“FibroGen China”) to AstraZeneca Treasury Limited under a share purchase agreement dated February 20, 2025.
The China State Administration for Market Regulation decided not to prohibit AstraZeneca’s acquisition of FibroGen China, which includes all of FibroGen’s roxadustat assets in China. The transaction is subject to customary closing conditions and deliverables and is expected to close in the third quarter of 2025.
FibroGen and its subsidiary FibroGen China Anemia Holdings, Ltd. will sell all issued and outstanding equity interests of FibroGen International (Hong Kong) Ltd. to AstraZeneca, FibroGen’s long-time commercialization partner for roxadustat in greater China and South Korea. FibroGen will retain rights to roxadustat in the United States, Canada, Mexico, and in markets not already held by AstraZeneca or licensed to Astellas Pharma Inc. in Europe, Japan, and certain other territories.
Armistice Capital, LLC and Steven Boyd report beneficial ownership of 336,000 shares of FibroGen, Inc. common stock, representing 8.31% of the outstanding class based on the issuer's reported share count in its most recent 10-Q. Armistice Capital acts as investment manager to the Master Fund, the direct holder of the shares, and exercises shared voting and dispositive power over the reported securities. Mr. Boyd, as managing member of Armistice Capital, is similarly reported to have shared voting and dispositive power. The Master Fund disclaims direct beneficial ownership due to the investment management arrangement.
FibroGen, Inc. reported condensed consolidated results for the quarter ended June 30, 2025. Total assets were $178.1 million versus $214.5 million at year-end 2024, and the company reported a consolidated total deficit of $202.5 million. For continuing operations, total revenue was $1.35 million for the quarter and $4.09 million for the six months ended June 30, 2025. The company recorded a net loss of $7.6 million for the quarter and $3.0 million for the six-month period; income from discontinued operations was $6.08 million for the quarter and $27.49 million for six months.
The company entered a share purchase agreement to sell FibroGen International to AstraZeneca for $85 million plus the net cash in China, with closing expected in the third quarter of 2025 subject to China SAMR approval. Management disclosed substantial doubt about the company’s ability to continue as a going concern without closing the sale or obtaining additional financing and must satisfy a U.S. cash covenant of $18.75 million. The company has a $75 million senior secured term loan (principal) that is presented as current with maturity in May 2026 and a liability related to the sale of future revenues of approximately $63.0 million.
FibroGen, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025; the press release is included as Exhibit 99.1 and an Inline XBRL cover page is included as Exhibit 104.
The company states the press release is furnished (not deemed "filed") for purposes of Section 18 of the Exchange Act and will not be incorporated by reference into other SEC filings. This 8-K does not include numerical financial results within the filing text; investors should review Exhibit 99.1 for the detailed figures and disclosures.